

Jensen Yeung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5898008/publications.pdf>

Version: 2024-02-01

85
papers

1,013
citations

471509

17
h-index

580821

25
g-index

86
all docs

86
docs citations

86
times ranked

1146
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	6.7	65
2	Facial and neck erythema associated with dupilumab treatment: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1339-1347.	1.2	63
3	Uveal Melanoma: A Review of the Literature. <i>Oncology and Therapy</i> , 2018, 6, 87-104.	2.6	44
4	Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 155-157.	1.2	42
5	Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1019-1020.	1.2	37
6	Think beyond the Skin. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 22-27.	1.2	31
7	Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 579-586.	1.2	30
8	Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 237-241.	1.2	29
9	Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 801-803.	1.2	27
10	Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria. <i>European Journal of Dermatology</i> , 2017, 27, 455-463.	0.6	26
11	A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 623-626.	1.2	25
12	Multifocal lymphangi endotheliomatosis with thrombocytopenia. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, S214-S217.	1.2	24
13	Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1530-1532.	1.2	23
14	Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literature. <i>JAAD International</i> , 2021, 3, 79-87.	2.2	23
15	Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 290-296.	1.2	21
16	Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis. <i>Frontiers in Medicine</i> , 2021, 8, 682547.	2.6	20
17	Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1212-1214.	1.2	19
18	Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 79-86.	1.2	19

#	ARTICLE	IF	CITATIONS
19	Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study. <i>Australasian Journal of Dermatology</i> , 2018, 59, e11-e14.	0.7	18
20	Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 174-177.	1.2	18
21	Patch Testing During Immunosuppressive Therapy: A Systematic Review. <i>Dermatitis</i> , 2021, 32, 365-374.	1.6	18
22	Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 3S-14S.	1.2	16
23	Effect of dupilumab on allergic contact dermatitis and patch testing. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1772-1776.	1.2	15
24	Biologic treatment outcomes in mucous membrane pemphigoid: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 110-120.	1.2	15
25	Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 452-456.	1.2	14
26	Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series. <i>JAAD Case Reports</i> , 2018, 4, 310-313.	0.8	14
27	Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1049-1051.	1.2	14
28	Interleukin-17 Antagonists in the Treatment of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 109-114.	1.2	13
29	Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 591-601.	1.2	13
30	Psoriasis appearing after dupilumab therapy in atopic dermatitis: A case report. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2094045.	0.3	13
31	Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 422-423.	1.2	12
32	Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study. <i>JAAD International</i> , 2021, 4, 67-69.	2.2	12
33	Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1169-1171.	1.2	11
34	Maintenance of therapeutic response after 1-year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 953-956.	1.2	10
35	Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 391-393.	1.2	10
36	Reply to: "Skin damage among health care workers managing coronavirus disease 2019". <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e169-e170.	1.2	10

#	ARTICLE	IF	CITATIONS
37	Drug survival of guselkumab in patients with plaque psoriasis: A 2-year retrospective, multicenter study. <i>JAAD International</i> , 2021, 4, 49-51.	2.2	10
38	The Pattern of Musculoskeletal Complaints in Patients With Suspected Psoriatic Arthritis and Their Correlation With Physical Examination and Ultrasound. <i>Journal of Rheumatology</i> , 2021, 48, 214-221.	2.0	9
39	Alopecia Areata Related Paradoxical Reactions in Patients on Dupilumab Therapy: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 451-452.	1.2	9
40	Tofacitinib for the treatment of psoriasis and psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 400-410.	0.8	9
41	Steroid-Induced Osteonecrosis in Dermatology. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 358-360.	1.2	8
42	Drugs associated with development of porokeratosis: A systematic review. <i>Dermatologic Therapy</i> , 2021, 34, e14560.	1.7	8
43	Prevalence and Characteristics of Dupilumab-Induced Ocular Surface Disease in Adults With Atopic Dermatitis. <i>Cornea</i> , 2022, 41, 1242-1247.	1.7	8
44	Successful use of secukinumab in pustular psoriasis. <i>JAAD Case Reports</i> , 2016, 2, 470-472.	0.8	7
45	Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 424-425.	1.2	7
46	Drugs associated with development of pityriasis rubra pilaris: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1071-1081.	1.2	7
47	Stewart-Treves syndrome and other cutaneous malignancies in the context of chronic lymphedema: a systematic review. <i>International Journal of Dermatology</i> , 2022, 61, 62-70.	1.0	7
48	Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review. <i>Dermatologic Therapy</i> , 2021, 34, e15104.	1.7	7
49	Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients With Long-Term Dupilumab Use. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 527-528.	1.2	7
50	Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review. <i>JAAD International</i> , 2021, 3, 18-22.	2.2	6
51	Can We Separate Oral Lichen Planus from Allergic Contact Dermatitis and Should We Patch Test? A Systematic Review of Chronic Oral Lichenoid Lesions. <i>Dermatitis</i> , 2021, 32, 144-150.	1.6	6
52	Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 3S-23S.	1.2	6
53	Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 176-177.	1.2	5
54	Guselkumab dosing interval optimization in adult patients with psoriasis: A retrospective, multicenter case series. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1813-1814.	1.2	5

#	ARTICLE	IF	CITATIONS
55	Treatment outcomes in confluent and reticulated papillomatosis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 825-829.	1.2	5
56	A systematic review of eczematous eruptions in patients receiving biologic therapy. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1630-1635.	1.2	5
57	Apremilast and its role in psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 386-399.	0.8	5
58	Comparative Efficacy of Different Triage Methods for Psoriatic Arthritis: Results From a Prospective Study in a Rapid Access Clinic. <i>Arthritis Care and Research</i> , 2022, 74, 1254-1262.	3.4	4
59	Management of pediatric generalized pustular psoriasis using biologics: An evidence-based review. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 484-486.	1.2	4
60	Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 418-419.	1.2	3
61	Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2090567.	0.3	3
62	Development of morphea in patients receiving biologic therapies: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1081-1085.	1.2	3
63	Development of chronic cutaneous lupus erythematosus during biologic therapy: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 835-838.	1.2	3
64	A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy. <i>JAAD International</i> , 2021, 2, 37-39.	2.2	3
65	Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 553-554.	1.2	3
66	Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 468-473.	1.2	3
67	Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review. <i>International Journal of Dermatology</i> , 2023, 62, 12-21.	1.0	3
68	Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2692-2694.	2.2	3
69	Serpiginous mycosis fungoides in a 21-year-old man. <i>JAAD Case Reports</i> , 2015, 1, 82-84.	0.8	2
70	Off-label Uses of Topical Pimecrolimus. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 442-448.	1.2	2
71	Stevens Johnson Syndrome and Toxic Epidermal Necrolysis Reactions to BRAF and MEK Inhibitors in Patients with Melanoma: A Systematic Review. <i>Journal of the American Academy of Dermatology</i> , 2020, 85, 981-983.	1.2	2
72	Biologic treatment outcomes in refractory eosinophilic fasciitis: A systematic review of published reports. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	2

#	ARTICLE	IF	CITATIONS
73	Palisaded neutrophilic and granulomatous dermatitis following a long-standing monoclonal gammopathy: A case report. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2097956.	0.3	2
74	Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study. <i>JAAD International</i> , 2022, 6, 3-5.	2.2	2
75	MACEs Not Associated With the Use of Biologic Therapy for Psoriasis in Real-World Clinical Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 352-353.	1.2	1
76	Characteristics and Treatment Outcomes in Chromhidrosis: A Systematic Review. <i>Journal of the American Academy of Dermatology</i> , 2020, 85, 998-1002.	1.2	1
77	Eruptive Seborrheic Keratoses Are Associated With a Co-Occurring Malignancy in the Majority of Reported Cases: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 57-62.	1.2	1
78	A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, , 120347542210885.	1.2	1
79	Onset of Sarcoidosis in Patients on Biologic Therapy: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 512-513.	1.2	1
80	Lichenoid Drug Eruptions Associated With the Use of Biologic Therapy: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 521-522.	1.2	1
81	Patient-Centred Care When Treating Plaque Psoriasis With Secukinumab: Reasons for Discontinuing Treatment Outside of Randomized Controlled Trials. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 647-649.	1.2	0
82	Development of granuloma annulare in patients on biologic therapies: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1594-1597.	1.2	0
83	Impact of COVID-19 on Patient-Initiated Discontinuation of Omalizumab in Two Academic Hospital Clinics at the University of Toronto. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 534-535.	1.2	0
84	Development of dermatomyositis in patients on biologic therapy: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	0
85	Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses.. <i>Skin Therapy Letter</i> , 2022, 27, 1-4.	0.3	0